Administration of exogenous surfactants, including INFASURF, often rapidly improve oxygenation and lung compliance.  Following INFASURF administration, patients should be monitored so that oxygen and ventilatory support can be modified. During dosing with INFASURF, the most common adverse reactions reported in clinical trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), and ETT reflux (21%). These events were generally transient, and not associated with serious complications. If any of these events occur, administration should be interrupted and the infant's condition stabilized.
Legal Notice I Privacy Notice